Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
US Department of Justice
Fish and Richardson
Argus Health
Baxter
Colorcon
Express Scripts
McKesson
Accenture
Harvard Business School

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020251

« Back to Dashboard

NDA 020251 describes ZANTAC 25, which is a drug marketed by Glaxo Grp Ltd and is included in one NDA. Additional details are available on the ZANTAC 25 profile page.

The generic ingredient in ZANTAC 25 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. One hundred and forty-three suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
Summary for 020251
Tradename:ZANTAC 25
Applicant:Glaxo Grp Ltd
Ingredient:ranitidine hydrochloride
Patents:0
Therapeutic Class:Gastrointestinal Agents
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EFFERVESCENT;ORALStrengthEQ 150MG BASE
Approval Date:Mar 31, 1994TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:GRANULE, EFFERVESCENT;ORALStrengthEQ 150MG BASE/PACKET
Approval Date:Mar 31, 1994TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EFFERVESCENT;ORALStrengthEQ 25MG BASE
Approval Date:Apr 1, 2004TE:RLD:No

Expired US Patents for NDA 020251

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd ZANTAC 150 ranitidine hydrochloride GRANULE, EFFERVESCENT;ORAL 020251-002 Mar 31, 1994 ➤ Sign Up ➤ Sign Up
Glaxo Grp Ltd ZANTAC 150 ranitidine hydrochloride TABLET, EFFERVESCENT;ORAL 020251-001 Mar 31, 1994 ➤ Sign Up ➤ Sign Up
Glaxo Grp Ltd ZANTAC 150 ranitidine hydrochloride TABLET, EFFERVESCENT;ORAL 020251-001 Mar 31, 1994 ➤ Sign Up ➤ Sign Up
Glaxo Grp Ltd ZANTAC 150 ranitidine hydrochloride TABLET, EFFERVESCENT;ORAL 020251-001 Mar 31, 1994 ➤ Sign Up ➤ Sign Up
Glaxo Grp Ltd ZANTAC 150 ranitidine hydrochloride GRANULE, EFFERVESCENT;ORAL 020251-002 Mar 31, 1994 ➤ Sign Up ➤ Sign Up
Glaxo Grp Ltd ZANTAC 150 ranitidine hydrochloride GRANULE, EFFERVESCENT;ORAL 020251-002 Mar 31, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Express Scripts
Johnson and Johnson
Citi
US Army
Medtronic
Baxter
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot